Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers

Nicotine Dependence Clinical Trial

— RIMA  

Official title:

Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01926626
• Other study ID #: Pro00044174
• Secondary ID: P50DA027840-01
• Status: Completed
• Phase: Phase 2
• First received: August 19, 2013
• Last updated: August 17, 2017
• Start date: September 2013
• Est. completion date: October 2014

Study information

• Verified date: August 2017
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The proposed study will assess the efficacy of moclobemide, a selective, reversible MAO-A inhibitor, in facilitating smoking cessation in treatment-seeking female smokers. This rationale is based on several findings from previous work: 1) cigarette smoke contains constituents that inhibit both forms of the enzyme monoamine oxidase (MAO-A and MAO-B); 2) that severity of depression symptoms after smoking abstinence is correlated with the level of MAO-A inhibition previously obtained from smoking; 3) moclobemide, an MAO-A inhibitor was found efficacious in a smoking cessation treatment trial (Berlin et al., 1995); and 4) women show a greater association between smoking and depression than men and women smokers in our previous trials report smoking to alleviate symptoms of depression to a greater extent than men.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 76
• Est. completion date: October 2014
• Est. primary completion date: July 2014
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Have no known serious medical conditions;

• Female;

• Are 18-65 years old;

• Smoke an average of at least 20 cigarettes per day;

• Have smoked at least one cumulative year;

• Have a Fagerstrom Test for Nicotine Dependence score of at least 5;

• Have an expired air carbon monoxide (CO) reading of at least 10ppm;

• Able to read and understand English;

• Express a desire to quit smoking in the next thirty days.

Potential subjects must agree to avoid the following during their participation in this study:

• excessive alcohol consumption;

• use of other antidepressants;

• general anesthesia;

• participation in any other nicotine-related modification strategy outside of this protocol;

• use of tobacco products other than cigarettes, including pipe tobacco, cigars, e-cigarettes, snuff, and chewing tobacco;

• use of experimental (investigational) drugs or devices;

• use of illegal drugs;

• cimetidine;

• Tyramine rich foods;

• use of opiate medications.

Exclusion Criteria:

• Hypertension;

• Hypotension with symptoms;

• Coronary heart disease;

• Lifetime history of heart attack;

• Cardiac rhythm disorder;

• Chest pains;

• Cardiac (heart) disorder;

• Active skin disorder;

• Liver or kidney disorder;

• Gastrointestinal problems or disease other than gastroesophageal reflux or heartburn;

• Active ulcers in the past 30 days;

• Currently Symptomatic lung disorder/disease;

• Brain abnormality;

• Migraine headaches that occur more frequently than once per week;

• Recent, unexplained fainting spells;

• Problems giving blood samples;

• Diabetes (unless controlled by diet and exercise alone);

• Current cancer or treatment for cancer in the past six;

• Other major medical condition;

• Current psychiatric disease;

• Suicidal ideation (within the past 10 years) or lifetime occurrence of attempted suicide;

• Current depression;

• Bulimia or anorexia;

• Use (within the past 45 days) of psychiatric medications including antidepressants and anti-psychotics;

• Use (within the past 30 days) of:

• Illegal drugs (or if the urine drug screen is positive for tetrahydrocannabinol (THC), Cocaine, Amphetamine, Opiates, Methamphetamines, phencyclidine (PCP), Benzodiazepines, or Barbiturates),

• Experimental (investigational) drugs;

• Any medications that are known to affect smoking cessation (e.g. clonidine);

• Smokeless tobacco (chewing tobacco, snuff), pipes or e-cigarettes;

• Wellbutrin, bupropion, Zyban, Chantix, nicotine replacement therapy or any other smoking cessation aid.

• Use of opiate medications for pain or sleep (non-opiate medication for pain or sleep will be allowed) within the past 14 days;

• Smokes more than one cigar a month.

• Alcohol abuse;

• Significant adverse reaction to nicotine patches, in the past.

• Known hypersensitivity to moclobemide or other MAO-A inhibitors.

• Current participation or recent participation (in the past 30 days) in another smoking study at our center or another research facility.

• Current participation or recent participation (in the past six months) in another medical research study.

Related Conditions & MeSH terms

• Nicotine Dependence
• Tobacco Use Disorder

Intervention

Drug:
• Nicotine Patch
Pre-Quit Period: 2 weeks of patch use (21mg/24hr) Post Quit Period: 10 weeks of patch use (21mg/24hr for 6 weeks, 14mg/24hr for 2 weeks, and 7mg/24hr for 2 weeks)
• Moclobemide
Pre-Quit Period: 1 week of moclobemide use (400 mg/day in 2 divided doses) Post Quit Period: 10 weeks of moclobemide use (400 mg/day in 2 divided doses)

Locations

Country	Name	City	State
United States	Duke Center for Smoking Cessation	Charlotte	North Carolina
United States	Duke Center forSmoking Cessation	Durham	North Carolina
United States	Duke Center for Smoking Cessation	Winston-Salem	North Carolina

Sponsors (3)

Lead Sponsor	Collaborator
Jed E. Rose	National Institute on Drug Abuse (NIDA), Philip Morris USA, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Safety of Moclobemide + Nicotine Patch	Safety of the moclobemide + nicotine patch treatment will be assessed by tabulating the number of participants rating side effects > "moderate".	1, 2, 4, 7 and 11 weeks after starting Moclobemide + Nicotine Patch
Other	Tolerability of Moclobemide + Nicotine Patch	Tolerability of the moclobemide + nicotine patch treatment will be assessed by tabulating the number of participants requiring dose reductions (or discontinuation of medication).	1, 2, 4, 7 and 11 weeks after starting Moclobemide + Nicotine Patch
Primary	Continuous Four-week Abstinence From Smoking	Number of participants who reported continuous four-week abstinence from smoking (weeks 6-10 post target quit date), confirmed by expired air carbon monoxide (CO).	Weeks 6-10 post quit day
Secondary	Point Abstinence From Smoking at Six Months Post Quit	Number of participants who reported 7-day point abstinence from smoking at six months post quit, confirmed by expired air CO.	7 day point abstinence from smoking at six months post quit
Secondary	Continuous Ten Week Abstinence From Smoking	Number of participants who reported continuous ten-week abstinence from smoking (weeks 1-10 post quit day), confirmed by expired air CO.	10 weeks post quit day
Secondary	Percentage of Change in Smoking Withdrawal Symptoms	Withdrawal symptoms will be assessed by questionnaire on Quit Day, 1 week post quit, 3 weeks post quit, 6 weeks post quit,10 weeks post quit and 6 months post quit (if applicable) using the Shiffman-Jarvik questionnaire, which consists of 33-items rated from 1 to 7, where 1= not at all, 2= very little, 3= a little, 4= moderately, 5= a lot, 6= quite a lot, and 7= extremely. The 33 items are grouped into 8 subscales: Craving, Negative Affect, Appetite, Arousal, Somatic - Anxiety, Somatic - G.I., Somatic - Respiratory Tract, and Habit Withdrawal. The range of scores for each subscale will be 1-7, with higher scores indicating more of the withdrawal symptom having been experienced.	Quit day and 1 week, 3 weeks, 6 weeks, 10 weeks and 6 months post quit day
Secondary	Percentage of Change in Expired Air Carbon Monoxide (CO) During the First Week of Nicotine Patch Treatment.	The initial response to nicotine patch will be assessed by looking at the percent change in expired air carbon monoxide (CO) at the end of week one (Study Visit 2) relative to baseline (Study Visit 1).	Baseline and 1 week